Drug insight: aminosalicylates for the treatment of IBD. (Q36752659)

16 August 2017

1 reference

title

Drug insight: aminosalicylates for the treatment of IBD. (English)

1 reference

16 August 2017

Ole H Nielsen

1

1 reference

16 August 2017

Lars K Munck

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Nature Reviews Gastroenterology & Hepatology

16 August 2017

1 reference

16 August 2017

4

1 reference

16 August 2017

160-170

1 reference

16 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpgasthep0696

16 August 2017

0 references

cites work

Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

Effect of sulfasalazine on digoxin bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

Mesalamine and relapse prevention in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

An experiment to determine the active therapeutic moiety of sulphasalazine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's Disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Comparative tolerability of therapies for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Inflammatory bowel disease: management issues during pregnancy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Sulphasalazine and male infertility: reversibility and possible mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Mesalazine-induced reversible infertility in a young male

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Drug therapy: Sulfasalazine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Sulphasalazine: a review of 40 years' experience.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Psychological stress in IBD: new insights into pathogenic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Systematic review: adherence issues in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

A systematic review of the associations between dose regimens and medication compliance

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Cortisone in ulcerative colitis; final report on a therapeutic trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Assessing disease activity and disease activity indices for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Design issues and outcomes in IBD clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Sulphasalazine and salicylazosulphadimidine in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Treatment of ulcerative colitis with oral 5-aminosalicyclic acid in patients unable to take sulphasalazine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Second trial of mesalamine therapy in the treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0696

7 January 2021

Identifiers

DOI

10.1038/NCPGASTHEP0696

1 reference

Dimensions Publication ID

16 August 2017

0 references

1 reference